NASDAQ:IPSC

Century Therapeutics Stock Insider Trading

etoro logo Buy IPSC
*Your capital is at risk
$2.07
-0.100 (-4.61%)
At Close: Jun 03, 2026

Century Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 75.05. In total, the insiders bought 11.54M and sold 270.87K IPSC shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 100 transactions)
75.05
Buy 11.54M shares
Sell 270.87K shares
54% Buy Activity
Negligible or No Correlation
Sell Signal Low Confidence
Mar 12, 2026

Analysis Breakdown:

  • Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 75.05.
  • Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date Type Person Role Amount
May 15, 2026
Sell
Common Stock
F-InKind
Pfeiffenberger Brent
President And CEO
CEO / President 31 172
Value: $72.9K
May 04, 2026
Sell
Common Stock
S-Sale
Carr Douglas
SVP Finance & Operations
Officer 264
Value: $618
Apr 01, 2026
Sell
Common Stock
F-InKind
Cowan Chad
Chief Scientific Officer
Officer 1 365
Value: $3K
Mar 12, 2026
Sell
Common Stock
S-Sale
Russotti Gregory
See Remarks
Officer 10 076
Value: $25.7K
Mar 12, 2026
Sell
Common Stock
S-Sale
Carr Douglas
SVP Finance & Operations
Officer 7 043
Value: $18.0K
Mar 11, 2026
Sell
Common Stock
F-InKind
Pfeiffenberger Brent
President And CEO
CEO / President 55 397
Value: $151.2K
Mar 11, 2026
Sell
Common Stock
F-InKind
Cowan Chad
Chief Scientific Officer
Officer 1 431
Value: $4K
Mar 09, 2026
Sell
Common Stock
S-Sale
Russotti Gregory
See Remarks
Officer 479
Value: $1K
Mar 06, 2026
Sell
Common Stock
F-InKind
Pfeiffenberger Brent
President And CEO
CEO / President 463
Value: $1K
Feb 13, 2026
Sell
Common Stock
F-InKind
Pfeiffenberger Brent
President And CEO
CEO / President 31 172
Value: $54.6K
Feb 03, 2026
Sell
Common Stock
S-Sale
Carr Douglas
SVP Finance & Operations
Officer 323
Value: $589
Feb 02, 2026
Buy
Stock Option (right to buy)
A-Award
Cowan Chad
Chief Scientific Officer
Officer 265 000
Value: $487.6K
Feb 02, 2026
Buy
Common Stock
A-Award
Cowan Chad
Chief Scientific Officer
Officer 135 000
Value: $248.4K
Feb 02, 2026
Buy
Stock Option (right to buy)
A-Award
Russotti Gregory
See Remarks
Officer 265 000
Value: $487.6K
Feb 02, 2026
Buy
Common Stock
A-Award
Pfeiffenberger Brent
President And CEO
CEO / President 475 000
Value: $874.0K
Feb 02, 2026
Buy
Stock Option (right to buy)
A-Award
Pfeiffenberger Brent
President And CEO
CEO / President 945 000
Value: $1.74M
Feb 02, 2026
Buy
Common Stock
A-Award
Russotti Gregory
See Remarks
Officer 135 000
Value: $248.4K
Feb 02, 2026
Buy
Common Stock
A-Award
Carr Douglas
SVP Finance & Operations
Officer 110 000
Value: $202.4K
Feb 02, 2026
Buy
Stock Option (right to buy)
A-Award
Carr Douglas
SVP Finance & Operations
Officer 225 000
Value: $414.0K
Jan 02, 2026
Sell
Common Stock
F-InKind
Cowan Chad
Chief Scientific Officer
Officer 1 611
Value: $2K
Dec 22, 2025
Buy
Common Stock
P-Purchase
Cowan Chad
Chief Scientific Officer
Officer 58 060
Value: $49.3K
Dec 12, 2025
Buy
Common Stock
P-Purchase
Pfeiffenberger Brent
President And CEO
CEO / President 52 000
Value: $30.4K
Dec 10, 2025
Sell
Common Stock
F-InKind
Pfeiffenberger Brent
President And CEO
CEO / President 463
Value: $244
Dec 09, 2025
Buy
Stock Option (right to buy)
A-Award
Murphy Martin Patrick
Director
Director 88 000
Value: $52.1K
Dec 09, 2025
Buy
Common Stock
J-Other
Murphy Martin Patrick
Insider
Other 0
Value: $0

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT CENTURY THERAPEUTICS, INC.
Century Therapeutics
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting C...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE